Our FluidFM solutions bring significant benefits to a wide range of applications in life sciences, biophysics and mechanobiology. Benefit from quantitative volume measurements of injected compounds during drug development, improved CRISPR gene editing by direct delivery into the nucleus, 2.5D nano-printing down to sub-micron levels or single cell adhesion and colloidal probe measurements.
Cytosurge AG develops, manufactures and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology. At the heart of the technology are the patented hollow FluidFM probes which have apertures down to 300 nm enabling the handling of femtoliter volumes.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2009
  • Number of employees in Switzerland
    10-19